Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models
Year: 2012
Type: review
Abstract: Parkinson's disease (PD) is the second most common neurodegenerative disorder. Several single gene mutations have been linked to this disease. Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) indicate LRRK2 as promising therapeutic target for the treatment of PD. LRRK2 mutations were observed in sporadic as well as familial PD patients and have been investigated intensively. LRRK2 is a large and complex protein, with multiple enzymatic and protein-interaction domains, each of which is effected by mutations. The most common mutation in PD patients is G2019S. Several LRRK2 inhibitors have been reported already, although the crystal structure of LRRK2 has not yet been determined. This review provides a summary of known LRRK2 inhibitors and will discuss recent in vitro and in vivo results of these inhibitors.
Source: ACS Chemical Neuroscience
DOI: 10.1021/cn200117j
Authors: Thomas Kramer, Fabio Lo Monte, Stefan Göring, Ghislaine Marlyse Okala Amombo, Boris Schmidt
Institution: Technische Universität Darmstadt
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1966262422
